跳转至内容
Merck

Safety review: squalene and thimerosal in vaccines.

Therapie (2010-12-24)
Marc Montana, Pierre Verhaeghe, Caroline Ducros, Thierry Terme, Patrice Vanelle, Pascal Rathelot
摘要

Few studies show the reluctance of the people to get vaccinated against A (H1N1) influenza for fear of side effects of squalene (MF59, AS03, AF03) and thimerosal. The aim of this paper is to assess the safety in using these adjuvants and preservative reviewing data of clinical trials relative to which formulation includes these compounds. In the current state of knowledge, these vaccines have proved to be effective even though they more frequently give local adverse events than non-adjuvanted influenza vaccines. Systemic side effects are generally not serious. In the studies, adjuvanted vaccines do not increase neither the risk of Guillain Barre syndrome nor auto-immune diseases. There is no convincing evidence that exposure to thimerosal in vaccines had any deletorious effect on physiological outcome.

材料
货号
品牌
产品描述

Sigma-Aldrich
硫柳汞钠, 97.0-101.0% (on dried substance, titration)
Sigma-Aldrich
角鲨烯, ≥98%, liquid
Supelco
角鲨烯, analytical standard
硫柳汞钠, European Pharmacopoeia (EP) Reference Standard